Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection

AIM: Lamivudine (LAM) and adefovir dipivoxil (ADV) are widely used in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but few studies have directly compared their therapeutic efficacy and treatment cost. This study aims to compare LAM with ADV head-to-head in these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jian-Hong, Ke, Yang, Zhu, Shao-Liang, Wang, Lin, Luo, Cheng-Piao, Gong, Wen-Feng, You, Xue-Mei, Ma, Liang, Xiang, Bang-De, Li, Le-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108611/
https://www.ncbi.nlm.nih.gov/pubmed/27877054
http://dx.doi.org/10.2147/OTT.S120062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108611/
https://www.ncbi.nlm.nih.gov/pubmed/27877054
http://dx.doi.org/10.2147/OTT.S120062

Ejemplares similares